Read by QxMD icon Read

Who ovarian cancer

Paul DiSilvestro, Angeles Alvarez Secord
Approximately 1% of women in the United States will be diagnosed with epithelial ovarian cancer (EOC) during their lifetime. It is most likely to present at a more advanced stage, requiring aggressive therapeutic measures, and most women will succumb to this illness. Due to advancements in therapy, the oncology community has begun to shift its focus to molecular targeted agents, alternative dosing schedules, and maintenance therapy. Women who achieve a response to initial adjuvant chemotherapy may be candidates for maintenance therapy, with the goal of inducing a lasting remission or prolonging the disease-free interval before recurrence...
June 5, 2018: Cancer Treatment Reviews
Jessica S Armer, Lauren Clevenger, Lauren Z Davis, Michaela Cuneo, Premal H Thaker, Michael J Goodheart, David P Bender, Laila Dahmoush, Anil K Sood, Steven W Cole, George M Slavich, Susan K Lutgendorf
BACKGROUND: Patients with ovarian cancer often report elevated anxiety at diagnosis that decreases posttreatment. However, a minority of patients experience sustained anxiety. Few studies have examined risk factors for persistent anxiety or its physiologic sequelae in ovarian cancer. Therefore, the authors investigated associations between prior life events, anxiety, inflammation (plasma levels of interleukin-6), and diurnal cortisol profiles in patients with ovarian cancer during the first year postdiagnosis...
June 15, 2018: Cancer
Ilana Graetz, Janeane N Anderson, Caitlin N McKillop, Edward J Stepanski, Andrew J Paladino, Todd D Tillmanns
OBJECTIVE: Nearly 1 in 5 patients hospitalized for ovarian cancer surgery are readmitted for complications that may have been prevented with monitoring. We conducted a randomized controlled feasibility trial to evaluate a postoperative web-based app intervention to provide real-time symptom monitoring among patients diagnosed or with suspected gynecological cancer who had open bilateral salpingo-oophorectomy surgery. METHODS: Participants were randomized into two groups: (1) App + Reminder: had access to the app, and use was encouraged with daily and/or weekly reminders; (2) app: had access to the app but received no reminders...
June 11, 2018: Gynecologic Oncology
Tingyan Shi, Rong Jiang, Jinjin Yu, Huijuan Yang, Dongsheng Tu, Zhiyuan Dai, Yang Shen, Yuqin Zhang, Xi Cheng, Huixun Jia, Ruiqin Tu, Huaying Wang, Jie Tang, Yuting Luan, Shumo Cai, Rongyu Zang
BACKGROUND: We assessed the efficacy of adding intraperitoneal (IP) chemotherapy to standard first-line intravenous (IV) chemotherapy in epithelial ovarian cancer (EOC) patients. METHODS: Patients with stage IIIC-IV EOC who underwent optimal debulking surgery were randomly assigned to four cycles of weekly IP chemotherapy with cisplatin (50 mg/m2 ) and etoposide (100 mg/m2 ) followed by six cycles of IV chemotherapy every 3 weeks (IP/IV arm), or were administered IV chemotherapy alone (IV arm)...
June 14, 2018: British Journal of Cancer
Pen Li, Alison Graver, Sarah Hosseini, Sunita Mulpuru, Lorraine Cake, Lynn Kachuik, Tinghua Zhang, Kayvan Amjadi
BACKGROUND: Tunnelled pleural catheters used to treat malignant pleural effusions may achieve pleurodesis. We aimed to identify factors associated with higher pleurodesis rates and earlier catheter removal. METHODS: We retrospectively reviewed a prospective database of tunnelled pleural catheters inserted consecutively between May 2006 and June 2013 for confirmed malignant pleural effusion. The cohort included patients who underwent medical thoracoscopy. Clinical, radiologic and pleural fluid data were recorded...
April 2018: CMAJ Open
Dimitrios Nasioudis, Evelyn Minis, Eloise Chapman-Davis, Melissa K Frey, Thomas A Caputo, Steven S Witkin, Kevin Holcomb
STUDY OBJECTIVE: Evaluate the prevalence, trends and outcomes of minimally invasive surgical staging (MIS) of malignant ovarian germ cell tumors (MOGCTs) apparently confined to the ovary. DESIGN: Retrospective cohort study (Canadian Task Force classification II-2) SETTING: Participating hospitals in the National Cancer Data Base PATIENTS: Women diagnosed between 2010-2014 with a MOGCT apparently confined to the ovary with information on the planned surgical approach...
June 8, 2018: Journal of Minimally Invasive Gynecology
Shitanshu Uppal, Ryan J Spencer, Laurel W Rice, Marcela G Del Carmen, R Kevin Reynolds, Jennifer J Griggs
OBJECTIVE: To evaluate the role of 30-day readmission rate as a quality of care metric in patients undergoing ovarian cancer surgery. METHODS: We performed a retrospective cohort study of women diagnosed between 2004 and 2013 with advanced-stage, high-grade, serous carcinoma who underwent primary treatment. Using the National Cancer Database, we compared the performance of hospital risk-adjusted 30-day readmission rate to other quality of care metrics (risk-adjusted 30- and 90-day mortality, rates of adherence to guideline-based care, and overall survival) within hospitals categorized by yearly case volume (10 or less, 11-20, 21-30, and 31 cases per year or more)...
June 6, 2018: Obstetrics and Gynecology
Yusuke Tajima, Hidetaka Eguchi, Noriyasu Chika, Tomonori Nagai, Sariya Dechamethakun, Kensuke Kumamoto, Tetsuhiko Tachikawa, Kiwamu Akagi, Jun-Ichi Tamaru, Hiroyuki Seki, Yasushi Okazaki, Hideyuki Ishida
Background: The prevalence and molecular characteristics of defective mismatch repair epithelial ovarian cancers in the Japanese population have scarcely been investigated. Methods: Immunohistochemistry for mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) was performed in formalin-fixed paraffin-embedded sections prepared from resected primary epithelial ovarian cancers in patients who underwent oophorectomy at our institution between April 2005 and September 2014...
June 8, 2018: Japanese Journal of Clinical Oncology
Amrutha Ramachandran, Anupama Rajanbabu, Kiran Gulabrao Bagul, Keechilat Pavithran, Dehannathparambil K Vijaykumar
The purpose of this study was to correlate the pattern of spread with oncological outcomes in advanced ovarian cancer patients. This is a retrospective analysis of 55 consecutive patients who had advanced epithelial ovarian cancer or primary peritoneal carcinomatosis (stages 3C and 4) with primary surgical intervention as the initial modality of treatment. Based on the spread of disease, they were further classified into class A: disease confined to the pelvis (excluded); class B: disease extending to the lower abdomen and omentum; class C: diffuse small-bowel disease with or without A, B, or D; and class D: disease in the upper abdomen...
June 2018: Indian Journal of Surgical Oncology
Engin Oral, Ovgu Aydin, Banu Aygun Kumbak, Sennur İlvan, Handan Yilmaz, Esra Tustas, Tugan Bese, Fuat Demirkiran, Macit Arvas
The aim of the study was to reveal the prevalence of concomitant endometriosis in malignant and borderline ovarian tumours. A retrospective analysis was performed of 530 patients with malignant ovarian tumours and 131 with borderline ovarian tumours, who underwent surgery in our hospital between 1995 and 2011. Forty-eight (7.3%) of 661 patients with malignant and borderline ovarian tumours were associated with endometriosis. Of the 48 endometriosis cases, 73% of those were atypical. Infertility was noted in 38% of patients with endometriosis-associated ovarian tumours...
June 8, 2018: Journal of Obstetrics and Gynaecology: the Journal of the Institute of Obstetrics and Gynaecology
Eran Ben-Arye, Ofer Dahan, Ilanit Shalom-Sharabi, Noah Samuels
OBJECTIVE: To assess the impact of integrative medicine (IM) on cancer-related fatigue in patients undergoing chemotherapy for early and advanced breast and gynecological (ovarian, endometrial, and cervical) cancer. METHODS: Patients reporting significant levels of fatigue (on the Edmonton Symptom Assessment Scale (ESAS), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), or Measure Yourself Concerns and Wellbeing questionnaire (MYCAW)) were offered complementary and integrative medicine (CIM) treatments in addition to standard supportive care...
June 7, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
Natalia Teixeira, Marian J Mourits, Jan C Oosterwijk, Ingrid E Fakkert, Anthony R Absalom, Stephan J L Bakker, Peter van der Meer, Geertruida H de Bock
This cross-sectional study aimed to investigate the effect of premenopausal risk reducing salpingo-oophorectomy (RRSO) on the cholesterol profile of women at increased ovarian cancer risk and to assess possible effects of age at and time since RRSO. We included 207 women who underwent RRSO before menopausal age (52 years) attending the family cancer clinic of an academic hospital and 828 age-matched women from a general population cohort (PREVEND). Participants filled out a questionnaire on socio-demographic characteristics, lifestyle and medical history, had anthropometric measurements and provided blood samples for assessment of serum levels of total cholesterol, HDL-cholesterol and non-HDL-cholesterol...
June 7, 2018: Familial Cancer
Marius Wunderle, Gregor Olmes, Naiba Nabieva, Lothar Häberle, Sebastian M Jud, Alexander Hein, Claudia Rauh, Carolin C Hack, Ramona Erber, Arif B Ekici, Juliane Hoyer, Georgia Vasileiou, Cornelia Kraus, André Reis, Arndt Hartmann, Rüdiger Schulz-Wendtland, Michael P Lux, Matthias W Beckmann, Peter A Fasching
Over the last two decades genetic testing for mutations in BRCA1 and BRCA2 has become standard of care for women and men who are at familial risk for breast or ovarian cancer. Currently, genetic testing more often also includes so-called panel genes, which are assumed to be moderate-risk genes for breast cancer. Recently, new large-scale studies provided more information about the risk estimation of those genes. The utilization of information on panel genes with regard to their association with the individual breast cancer risk might become part of future clinical practice...
May 2018: Geburtshilfe und Frauenheilkunde
Oliver S Eng, Mustafa Raoof, Andrew M Blakely, Xian Yu, Stephen J Lee, Ernest S Han, Mark T Wakabayashi, Bertram Yuh, Byrne Lee, Thanh H Dellinger
BACKGROUND AND OBJECTIVES: Cytoreductive surgery with complete macroscopic resection in patients with ovarian cancer is associated with improved survival. Institutional reports of combined upper and lower abdominal cytoreductive surgery for more advanced disease have described multidisciplinary approaches. We sought to investigate outcomes in patients undergoing cytoreductive surgery in patients with upper and lower abdominal disease at our institution. METHODS: Patients who underwent cytoreductive surgery for ovarian malignancies from 2008 to 2015 were retrospectively identified from an institutional database...
June 7, 2018: Journal of Surgical Oncology
Martin P Nilsson, Erik D Nilsson, Barbro Silfverberg, Åke Borg, Niklas Loman
PURPOSE: This study aimed to evaluate predictors of testing uptake among unselected breast cancer patients who were offered germline BRCA1/2 testing in a prospective study. METHODS: Pretest information was provided by a standardized invitation letter instead of in-person counseling. Data was abstracted from medical records. Using multivariate logistic regressions, predictors of testing uptake were analyzed. RESULTS: The overall uptake of testing was 67% (539 of 805 patients)...
June 6, 2018: Genetics in Medicine: Official Journal of the American College of Medical Genetics
Wendy van Dorp, Riccardo Haupt, Richard A Anderson, Renee L Mulder, Marry M van den Heuvel-Eibrink, Eline van Dulmen-den Broeder, H Irene Su, Jeanette Falck Winther, Melissa M Hudson, Jennifer M Levine, W Hamish Wallace
Some survivors of childhood, adolescent, and young adult cancer are at increased risk of gonadal dysfunction and adverse pregnancy outcomes. We reviewed currently available literature that evaluated reproductive function and pregnancy outcomes of female cancer survivors diagnosed before the age of 25 years. High-dose alkylating agent chemotherapy and abdominal/pelvic radiotherapy adversely affect gonadal function in a dose-related fashion, with older age at exposure conferring greater risk as a result of the age-related decline in ovarian reserve...
June 6, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Rui Zheng, Mulong Du, Baoguo Zhang, Junyi Xin, Haiyan Chu, Min Ni, Zhengdong Zhang, Dongying Gu, Meilin Wang
Obesity is correlated with increased colorectal cancer (CRC) risk, but few studies have investigated lifetime body mass index (BMI) metrics and CRC risk. In a cohort of 139 229 subjects in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, we analysed the effects of life-course BMI trajectories on CRC risk. At 13 years of follow-up, 2031 subjects developed CRC. Compared with subjects who were never overweight/obese, subjects who first exceeded the threshold of 25 kg m-2 at age 20 had a higher CRC risk (HR = 1...
June 6, 2018: British Journal of Cancer
Leda Severi, Lorena Losi, Sergio Fonda, Laura Taddia, Gaia Gozzi, Gaetano Marverti, Fulvio Magni, Clizia Chinello, Martina Stella, Jalid Sheouli, Elena I Braicu, Filippo Genovese, Angela Lauriola, Chiara Marraccini, Alessandra Gualandi, Domenico D'Arca, Stefania Ferrari, Maria P Costi
Proteomics and bioinformatics are a useful combined technology for the characterization of protein expression level and modulation associated with the response to a drug and with its mechanism of action. The folate pathway represents an important target in the anticancer drugs therapy. In the present study, a discovery proteomics approach was applied to tissue samples collected from ovarian cancer patients who relapsed after the first-line carboplatin-based chemotherapy and were treated with pemetrexed (PMX), a known folate pathway targeting drug...
2018: Frontiers in Pharmacology
Nadine M Tung, Judy E Garber
Testing for germline BRCA1/2 mutations has an established predictive role in breast cancer risk assessment. More recently, studies have also identified BRCA1/2 status as clinically relevant in the selection of therapy for patients already diagnosed with breast cancer. Emerging breast and ovarian cancer research indicate that BRCA status predicts responsiveness to platinum-based chemotherapy, as well as to inhibitors of poly(ADP-ribose) polymerase (PARP), owing to the ability of these interventions to inhibit DNA repair pathways...
June 5, 2018: British Journal of Cancer
Prudence A Francis, Olivia Pagani, Gini F Fleming, Barbara A Walley, Marco Colleoni, István Láng, Henry L Gómez, Carlo Tondini, Eva Ciruelos, Harold J Burstein, Hervé R Bonnefoi, Meritxell Bellet, Silvana Martino, Charles E Geyer, Matthew P Goetz, Vered Stearns, Graziella Pinotti, Fabio Puglisi, Simon Spazzapan, Miguel A Climent, Lorenzo Pavesi, Thomas Ruhstaller, Nancy E Davidson, Robert Coleman, Marc Debled, Stefan Buchholz, James N Ingle, Eric P Winer, Rudolf Maibach, Manuela Rabaglio-Poretti, Barbara Ruepp, Angelo Di Leo, Alan S Coates, Richard D Gelber, Aron Goldhirsch, Meredith M Regan
Background In the Suppression of Ovarian Function Trial (SOFT) and the Tamoxifen and Exemestane Trial (TEXT), the 5-year rates of recurrence of breast cancer were significantly lower among premenopausal women who received the aromatase inhibitor exemestane plus ovarian suppression than among those who received tamoxifen plus ovarian suppression. The addition of ovarian suppression to tamoxifen did not result in significantly lower recurrence rates than those with tamoxifen alone. Here, we report the updated results from the two trials...
June 4, 2018: New England Journal of Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"